Periodic Reporting for period 1 - PROT-RESIST (Toward the Commercialization of a Proteolytically Resistant APPI Variant for Inhibiting Metastasis in Prostate and Pancreatic Cancer)

Distant site tumor metastases are the leading cause of cancer-related deaths, but nonetheless standard-of-care (SoC) treatments and other targeted therapies under development are based on activity against primary tumors rather than on anti-metastatic activity. Our ERC PoC...